Diss. (sammanfattning) Stockholm : Karolinska institutet, 2010. / Härtill 4 uppsatser.

A left ventricular thrombus develops in approximately 40% of patients following an anterior myocardial infarction. Embolization from these thrombi has been regarded as the most important cause of stroke following a myocardial infarction. The occurrence and characteristics of left ventricular thrombi and stroke after anterior myocardial infarction may, however, have changed after the introduction of aspirin and thrombolytics as standard therapy. The occurrence of left ventricular thrombi was examined in 99 patients with an acute anterior myocardial infarction, 74 of whom were treated with streptokinase. Thrombi were equally common in the thrombolysis group (46%, 95% confidence interval [Cl], 35-57%) as in the non-thrombolysis group (40%, 95% Cl, 21-59%). The risk of thrombus formation was related to the degree of left ventricular segmental dysfunction. Using serial echocardiographic examinations, the formation and resolution of thrombi was found to be highly dynamic. The majority of thrombi diagnosed during the hospital stay had resolved at follow-up one month later, irrespective of treatment with streptokinase or anticoagulants. The development of new thrombi was, however, observed at every follow-up examination interval. One-hundred-and-twenty-four patients suffering a stroke within 28 days of an acute myocardial infarction were identified in the northern Sweden MONICA stroke registry between 1985 and 1994. The overall event rate of ischemic myocardial infarction-related stroke was 1.07%. The risk of a stroke was highest duringt he first 5 days after the infarction. Only approximately half the strokes were preceded by an anterior myocardial infarction. In a case-control analysis, atrial fibrillation (chronic or new onset), ST elevation and a history of a previous stroke were found to be independent predictors of stroke. There was a long-term trend towards a lower incidence and event rate for myocardial infarction-related stroke. Clinical stroke characteristics were examined in 103 patients with a first-ever stroke within 28 days of a myocardial infarction and compared with stroke characteristics in 206 control subjects without a recent myocardial infarction. The sudden onset of neurological symptoms, an impairment of consciousness, a progression in neurological deficits and a stroke of the total anterior circulation infarction subclass were more common in cases than in controls. The risk of a recurrent stroke during one year of follow-up was not influenced by a recent myocardial infarction, but patients who had suffered a myocardial infarction had markedly higher mortality. To conclude, thrombolytic treatment does not reduce the occurrence of left ventricular thrombi after a myocardial infarction. The risk of thrombus formation is related to the extent of the myocardial injury. The development and resolution of thrombi is a highly dynamic process. There is a long-term trend towards a lower incidence and event rate of ischemic stroke after a myocardial infarction. Although the clinical stroke characteristics differ, they are not specific enough to differentiate between patients with and without a recent myocardial infarction. / <p>S. 1-84: sammanfattning, s. 85-136: 5 uppsatser</p> / digitalisering@umu

Diss. (sammanfattning) Stockholm : Karol inst., 2003. / Härtill 5 uppsatser.

In 1996, the United States Food and Drug Administration officially approved the use of intravenous recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke, with the requirement that a baseline computed tomography (CT) scan be performed to rule out acute intracerebral or subarachnoid hemorrhage. Today, the American Heart Association (AHA) Stroke Council acknowledges magnetic resonance imaging (MRI) as more sensitive to the detection of ischemia, and yet, guidelines released by the group suggest that either CT or MRI may serve as the primary, hyperacute imaging modality. The AHA recommends that for most cases, non-contrast-enhanced CT scans provide sufficient information for medical management decisions. A systematic review of published literature was conducted to compare current capabilities of CT and MRI in an effort to determine which imaging modality should be used in the setting of acute ischemic stroke. Current research indicates that MRI is comparable to CT in the detection of acute hemorrhage, but superior in the detection of acute ischemia. In addition, MRI has demonstrated the ability to not only identify suitable patients for treatment, but also identify patients whose treatment would be unnecessary and potentially dangerous. Therefore, the hope is that clinical guidelines, like those released by the AHA Stroke Council, will be modified to promote MRI as the primary imaging modality. A modification to the major clinical guidelines will initiate a change in the approach of acute stroke evaluation across all clinical stroke centers.

Introdução e objetivos: A extensão segura da janela terapêutica para o tratamento do acidente vascular cerebral isquêmico (AVCI) agudo com terapia trombolítica endovenosa (EV) é importante, porque mais pacientes podem ser beneficiados com este tratamento. O objetivo é comparar o benefício da trombólise <3 horas e entre 3 e 4,5 horas no mundo real. Métodos: Avaliamos prospectivamente pacientes com AVCI tratados com trombólise em Porto Alegre entre 2002 a 2011. Até 2008, apenas alguns pacientes selecionados foram tratados com mais de 3 horas. Após o estudo ECASS III, estendemos a janela terapêutica com os mesmos critérios para os pacientes tratados entre 3-4,5 h. Nós comparamos a evolução funcional em 3 meses, hemorragia intracerebral sintomática (HIS) e mortalidade do grupo tratado < 3h com o grupo tratado entre 3-4,5h. Resultados: Foram analisados 487 pacientes com AVCI agudo trombolisados. Neste período, 33% dos pacientes foram tratados entre 3 e 4,5 horas. Pacientes tratados mais precocemente eram mais graves: média de idade 68±14 vs. 65±13, P<0,03, escore do NIHSS 12±6 vs. 11±7, P<0,015, ASPECTS ≤ 7 18% vs. 8,5%, P=0,011, hipodensidade maior 1/3 ACM na tomografia (4% vs. 0,9%, P=0,05). Os resultados no grupo < 3 h comparado com o grupo entre 3-4,5h foram, respectivamente: boa evolução funcional 49% vs. 50%, P= 0,82, mortalidade 12% vs. 11%, P= 0,60 e a HIS 5,9% vs. 3,8%, P= 0,52. Após a extensão da janela terapêutica, houve um aumento de 3,8 vezes no número de pacientes trombolisados. Conclusões: Este estudo sugere que trombólise EV para pacientes com AVCI agudo entre 3-4,5h é segura e apresenta bons resultados funcionais, semelhante a pacientes tratados mais precocemente. Deve ser estimulado o tratamento o mais precoce possível, mas pacientes que chegam tardíamente ao hospital também podem receber o benefício do tratamento. / Background and aims: A safe extension of the therapeutic window for treating acute ischemic stroke (AIS) with intravenous thrombolysis is important because it would mean that more patients could receive the benefit of the treatment. Our goal was to compare the safety and functional outcome of thrombolysis between 3 and 4.5 h and ≤ 3 h in patients in the Real World. Methods: We prospectively evaluated a cohort of thrombolyzed patients treated between 2005 and 2011. Following the publication of the results from ECASS III, we extended the therapeutic window, using the same criteria, to patients treated between 3 and 4.5 h after AIS. We compared functional outcomes at 3 months, symptomatic intracranial hemorrhage (SIH) and mortality of the patients treated until 3 h vs. those treated at between 3 and 4.5 h. Results: We analyzed 487 thrombolyzed patients. During this period, 33% of patients were treated between 3 and 4.5 hours. The patients treated at earlier timepoints were more severely affected than the patients treated at later timepoints: mean ages were 68 vs. 65 (P<0.03), NIHSS scale scores were 12 vs. 11 (P<0.015), ASPECTS ≤ 7 were 18% vs. 8.5% (P =0.011) and hypodensity was observed in more than 1/3 of the middle cerebral artery in 4% vs. 0.9% (P=0.05), respectively. When comparing the group < 3 h vs. between 3 and 4.5h, the results showed favorable outcomes in 49% vs. 50% (P=0.82), mortality in 12% vs. 11% (P=0.60) and SIH in 5.9% vs. 3.8% (P=0.52), respectively. After extending the therapeutic window, the number of thrombolyzed patients increased 3.8-fold. Conclusions: This study suggests that intravenous thrombolysis is safe in AIS patients and that it causes favorable functional outcomes, similar to patients treated at earlier timepoints. Thrombolytic treatment should be initiated as soon as possible; however, patients who arrive late may receive treatment benefits.

Submitted by PRISCILA WATSON RIBEIRO null (priwtr@yahoo.com.br) on 2017-04-03T00:59:46Z No. of bitstreams: 1 Doutorado Priscila Final.pdf: 863235 bytes, checksum: b23835e505c931b9c7f5fdcf434d43ad (MD5) / Rejected by Juliano Benedito Ferreira (julianoferreira@reitoria.unesp.br), reason: Solicitamos que realize uma nova submissão seguindo as orientações abaixo: No campo “Versão a ser disponibilizada online imediatamente” foi informado que seria disponibilizado o texto completo porém no campo “Data para a disponibilização do texto completo” foi informado que o texto completo deverá ser disponibilizado apenas 6 meses após a defesa. Caso opte pela disponibilização do texto completo apenas 6 meses após a defesa selecione no campo “Versão a ser disponibilizada online imediatamente” a opção “Texto parcial”. Esta opção é utilizada caso você tenha planos de publicar seu trabalho em periódicos científicos ou em formato de livro, por exemplo e fará com que apenas as páginas pré-textuais, introdução, considerações e referências sejam disponibilizadas. Se optar por disponibilizar o texto completo de seu trabalho imediatamente selecione no campo “Data para a disponibilização do texto completo” a opção “Não se aplica (texto completo)”. Isso fará com que seu trabalho seja disponibilizado na íntegra no Repositório Institucional UNESP. Por favor, corrija esta informação realizando uma nova submissão. Agradecemos a compreensão. on 2017-04-07T14:53:15Z (GMT) / Submitted by PRISCILA WATSON RIBEIRO null (priwtr@yahoo.com.br) on 2017-04-07T17:01:13Z No. of bitstreams: 1 Doutorado Priscila Final.pdf: 863235 bytes, checksum: b23835e505c931b9c7f5fdcf434d43ad (MD5) / Approved for entry into archive by Luiz Galeffi (luizgaleffi@gmail.com) on 2017-04-11T19:08:43Z (GMT) No. of bitstreams: 1 ribeiro_pw_dr_bot.pdf: 863235 bytes, checksum: b23835e505c931b9c7f5fdcf434d43ad (MD5) / Made available in DSpace on 2017-04-11T19:08:43Z (GMT). No. of bitstreams: 1 ribeiro_pw_dr_bot.pdf: 863235 bytes, checksum: b23835e505c931b9c7f5fdcf434d43ad (MD5) Previous issue date: 2017-03-03 / Introdução: A terapia de reperfusão cerebral é uma das modalidades de tratamento do Acidente Vascular Cerebral (AVC) agudo capaz de promover a recuperação dos déficits neurológicos e a redução da incapacidade funcional. A restauração do fluxo sanguíneo pela ação do trombolítico em áreas corticais específicas pode minimizar o grau de comprometimento da disfagia orofaríngea bem como suas complicações. Objetivo: analisar e comparar o desempenho de parâmetros qualitativos e quantitativos específicos da deglutição em indivíduos pós-AVC trombolisados e não trombolisados. Casuística e Método: Estudo coorte prospectivo. Participaram no estudo 32 indivíduos pós-AVC isquêmico, sendo 19 trombolisados (grupo 1) e 13 não trombolisados (grupo 2). Realizado o exame de videofluoroscopia da deglutição e análise da penetração laríngea e aspiração laringotraqueal, Início da Resposta Faríngea (IRF), Tempo de Trânsito Faríngeo (TTF), além do nível de ingestão oral e ocorrência de pneumonia nos primeiros cinco dias após o tratamento de reperfusão cerebral e em 30 dias após o AVC. Resultados: Na comparação entre os grupos em relação à penetração laríngea e aspiração, o grupo de pacientes não trombolisados apresentou maiores índices de penetração laríngea com líquido na avaliação de 30 dias (p=0,007). Quanto às medidas temporais de IRF e TTF, ambos os grupos apresentaram pacientes com alterações nos dois momentos de avaliação, sem diferença estatística entre eles (p=0.646 e p=1,000). A evolução no nível de ingestão oral foi maior no grupo de pacientes trombolisados, sendo que todos atingiram o nível 7 da FOIS (Escala Funcional de Ingestão Oral) na avaliação de 30 dias sem significância estatística (p=0,020). Não houve diferença significativa entre os grupos quanto à presença de pneumonia, 16% no G1 e 15% no G2 na avaliação dos primeiros cinco dias. Conclusão: Os dois grupos apresentaram evoluções nos parâmetros de deglutição em relação aos dois momentos de avaliação. No entanto, não houve diferença ao comparar os indivíduos trombolisados e não trombolisados em relação aos parâmetros quantitativos e qualitativos da deglutição. / Background: The cerebral reperfusion therapy is one of the treatments for stroke that promoting recovery of neurological deficits and reduction of functional incapacity. Restoration of blood flow by thrombolytic action in specific cortical areas may minimize the degree of impairment of oropharyngeal dysphagia as well as its complications. The aim of this study was to analyze and compare the performance of specific qualitative and quantitative parameters of swallowing in stroke patients who are both thrombolytic and non-thrombolytic. Method: Prospective cohort study. The study included 32 individuals after ischemic stroke, of which 19 thrombolytic (group 1) and 13 non-thrombolytic (group 2). The videofluoroscopy examination and analysis of laryngeal penetration and aspiration, pharyngeal swallow response (PSR), Pharyngeal Transit Time (PTT), oral intake level and occurrence of pneumonia in the first five days after treatment reperfusion and within 30 days after stroke. Results: In the comparison between the groups in relation to laryngeal penetration and aspiration, the group of non-thrombolytic patients presented higher rates of laryngeal penetration with fluid at the 30-day (p = 0.007). Regarding the temporal measures of PSR and PTT, both groups presented patients with alterations in the two moments of evaluation, without statistical significance between the groups (p = 0.646 and p = 1,000). The evolution in the level of oral intake was higher in the group of patients with thrombolysis, and all level 7 of the FOIS (Functional Oral Intake Scale) in the evaluation of 30 days without statistical significance (p = 0.020). There were no significant differences between the groups regarding of pneumonia, 16% in G1 and 15% in G2 in the evaluation of the first five days. Conclusion: The two groups showed changes in swallowing parameters in relation to the two moments of evaluation. However, there was no difference in comparing the thrombolytic and non-thrombolytic individuals in relation to the quantitative and qualitative parameters of swallowing.

Introdução e objetivos: A extensão segura da janela terapêutica para o tratamento do acidente vascular cerebral isquêmico (AVCI) agudo com terapia trombolítica endovenosa (EV) é importante, porque mais pacientes podem ser beneficiados com este tratamento. O objetivo é comparar o benefício da trombólise <3 horas e entre 3 e 4,5 horas no mundo real. Métodos: Avaliamos prospectivamente pacientes com AVCI tratados com trombólise em Porto Alegre entre 2002 a 2011. Até 2008, apenas alguns pacientes selecionados foram tratados com mais de 3 horas. Após o estudo ECASS III, estendemos a janela terapêutica com os mesmos critérios para os pacientes tratados entre 3-4,5 h. Nós comparamos a evolução funcional em 3 meses, hemorragia intracerebral sintomática (HIS) e mortalidade do grupo tratado < 3h com o grupo tratado entre 3-4,5h. Resultados: Foram analisados 487 pacientes com AVCI agudo trombolisados. Neste período, 33% dos pacientes foram tratados entre 3 e 4,5 horas. Pacientes tratados mais precocemente eram mais graves: média de idade 68±14 vs. 65±13, P<0,03, escore do NIHSS 12±6 vs. 11±7, P<0,015, ASPECTS ≤ 7 18% vs. 8,5%, P=0,011, hipodensidade maior 1/3 ACM na tomografia (4% vs. 0,9%, P=0,05). Os resultados no grupo < 3 h comparado com o grupo entre 3-4,5h foram, respectivamente: boa evolução funcional 49% vs. 50%, P= 0,82, mortalidade 12% vs. 11%, P= 0,60 e a HIS 5,9% vs. 3,8%, P= 0,52. Após a extensão da janela terapêutica, houve um aumento de 3,8 vezes no número de pacientes trombolisados. Conclusões: Este estudo sugere que trombólise EV para pacientes com AVCI agudo entre 3-4,5h é segura e apresenta bons resultados funcionais, semelhante a pacientes tratados mais precocemente. Deve ser estimulado o tratamento o mais precoce possível, mas pacientes que chegam tardíamente ao hospital também podem receber o benefício do tratamento. / Background and aims: A safe extension of the therapeutic window for treating acute ischemic stroke (AIS) with intravenous thrombolysis is important because it would mean that more patients could receive the benefit of the treatment. Our goal was to compare the safety and functional outcome of thrombolysis between 3 and 4.5 h and ≤ 3 h in patients in the Real World. Methods: We prospectively evaluated a cohort of thrombolyzed patients treated between 2005 and 2011. Following the publication of the results from ECASS III, we extended the therapeutic window, using the same criteria, to patients treated between 3 and 4.5 h after AIS. We compared functional outcomes at 3 months, symptomatic intracranial hemorrhage (SIH) and mortality of the patients treated until 3 h vs. those treated at between 3 and 4.5 h. Results: We analyzed 487 thrombolyzed patients. During this period, 33% of patients were treated between 3 and 4.5 hours. The patients treated at earlier timepoints were more severely affected than the patients treated at later timepoints: mean ages were 68 vs. 65 (P<0.03), NIHSS scale scores were 12 vs. 11 (P<0.015), ASPECTS ≤ 7 were 18% vs. 8.5% (P =0.011) and hypodensity was observed in more than 1/3 of the middle cerebral artery in 4% vs. 0.9% (P=0.05), respectively. When comparing the group < 3 h vs. between 3 and 4.5h, the results showed favorable outcomes in 49% vs. 50% (P=0.82), mortality in 12% vs. 11% (P=0.60) and SIH in 5.9% vs. 3.8% (P=0.52), respectively. After extending the therapeutic window, the number of thrombolyzed patients increased 3.8-fold. Conclusions: This study suggests that intravenous thrombolysis is safe in AIS patients and that it causes favorable functional outcomes, similar to patients treated at earlier timepoints. Thrombolytic treatment should be initiated as soon as possible; however, patients who arrive late may receive treatment benefits.

Introdução e objetivos: A extensão segura da janela terapêutica para o tratamento do acidente vascular cerebral isquêmico (AVCI) agudo com terapia trombolítica endovenosa (EV) é importante, porque mais pacientes podem ser beneficiados com este tratamento. O objetivo é comparar o benefício da trombólise <3 horas e entre 3 e 4,5 horas no mundo real. Métodos: Avaliamos prospectivamente pacientes com AVCI tratados com trombólise em Porto Alegre entre 2002 a 2011. Até 2008, apenas alguns pacientes selecionados foram tratados com mais de 3 horas. Após o estudo ECASS III, estendemos a janela terapêutica com os mesmos critérios para os pacientes tratados entre 3-4,5 h. Nós comparamos a evolução funcional em 3 meses, hemorragia intracerebral sintomática (HIS) e mortalidade do grupo tratado < 3h com o grupo tratado entre 3-4,5h. Resultados: Foram analisados 487 pacientes com AVCI agudo trombolisados. Neste período, 33% dos pacientes foram tratados entre 3 e 4,5 horas. Pacientes tratados mais precocemente eram mais graves: média de idade 68±14 vs. 65±13, P<0,03, escore do NIHSS 12±6 vs. 11±7, P<0,015, ASPECTS ≤ 7 18% vs. 8,5%, P=0,011, hipodensidade maior 1/3 ACM na tomografia (4% vs. 0,9%, P=0,05). Os resultados no grupo < 3 h comparado com o grupo entre 3-4,5h foram, respectivamente: boa evolução funcional 49% vs. 50%, P= 0,82, mortalidade 12% vs. 11%, P= 0,60 e a HIS 5,9% vs. 3,8%, P= 0,52. Após a extensão da janela terapêutica, houve um aumento de 3,8 vezes no número de pacientes trombolisados. Conclusões: Este estudo sugere que trombólise EV para pacientes com AVCI agudo entre 3-4,5h é segura e apresenta bons resultados funcionais, semelhante a pacientes tratados mais precocemente. Deve ser estimulado o tratamento o mais precoce possível, mas pacientes que chegam tardíamente ao hospital também podem receber o benefício do tratamento. / Background and aims: A safe extension of the therapeutic window for treating acute ischemic stroke (AIS) with intravenous thrombolysis is important because it would mean that more patients could receive the benefit of the treatment. Our goal was to compare the safety and functional outcome of thrombolysis between 3 and 4.5 h and ≤ 3 h in patients in the Real World. Methods: We prospectively evaluated a cohort of thrombolyzed patients treated between 2005 and 2011. Following the publication of the results from ECASS III, we extended the therapeutic window, using the same criteria, to patients treated between 3 and 4.5 h after AIS. We compared functional outcomes at 3 months, symptomatic intracranial hemorrhage (SIH) and mortality of the patients treated until 3 h vs. those treated at between 3 and 4.5 h. Results: We analyzed 487 thrombolyzed patients. During this period, 33% of patients were treated between 3 and 4.5 hours. The patients treated at earlier timepoints were more severely affected than the patients treated at later timepoints: mean ages were 68 vs. 65 (P<0.03), NIHSS scale scores were 12 vs. 11 (P<0.015), ASPECTS ≤ 7 were 18% vs. 8.5% (P =0.011) and hypodensity was observed in more than 1/3 of the middle cerebral artery in 4% vs. 0.9% (P=0.05), respectively. When comparing the group < 3 h vs. between 3 and 4.5h, the results showed favorable outcomes in 49% vs. 50% (P=0.82), mortality in 12% vs. 11% (P=0.60) and SIH in 5.9% vs. 3.8% (P=0.52), respectively. After extending the therapeutic window, the number of thrombolyzed patients increased 3.8-fold. Conclusions: This study suggests that intravenous thrombolysis is safe in AIS patients and that it causes favorable functional outcomes, similar to patients treated at earlier timepoints. Thrombolytic treatment should be initiated as soon as possible; however, patients who arrive late may receive treatment benefits.

A 53 year-old male presented with a one-day history of a swollen arm and dull, aching pain in the right upper extremity. The patient reported commencing exercising daily over the prior week with a modified, oscillating dumbbell; commonly referred to as a Shake Weight. Imaging revealed an occlusive thrombus in the right axillary, proximal brachial and basilic veins. The patient was treated with a 24-hour tPA infusion followed by mechanical thrombectomy, balloon angioplasty, and stent placement for a residual thrombus and stenosis. The patient was discharged the following day on warfarin and aspirin. This is the first report of effort-induced thrombosis of the upper extremity following the use of a modified, oscillating dumbbell. Due to the growing popularity of modified dumbbells and the possible risk for axillary vein thrombosis, consideration should be made to caution consumers of this potential complication.

Stroke thrombolysis is a method for restoring cerebral blood flow after ischemic stroke, with high priority in the Swedish national guidelines. implementation of stroke thrombolysis in Swedish routine stroke care has shown marked differences between demographic groups, hospital types, and regions. The general aim of this thesis were to examine the implementation of ischemic stroke thrombolysis in Swedish routine stroke care with an equity perspective; to gain more insight into the factors that influence implementation, how the treatment has reached patient groups, and differences in long-term outcomes between women and men. Analysis of data from research interviews with clinicians working within stroke care displayed that the facilitators of and barriers to the implementation of stroke thrombolysis could broadly be categorized into those related to individuals, to social interactions and context, and to organizational and resource issues. Key facilitating factors expressed in interviews were work pride and motivation, good leadership, involvement of all staff members in the implementation process, and quality assurance. Major barriers concerned lack of competence and experience, outdated attitudes regarding stroke management, counterproductive power structures, lack of continuity, and insufficient human resources. National quality register data displayed that stroke thrombolysis treatment expanded to reach more patients with mild deficits. Groups with higher education were more likely to receive treatment, compared to groups with lower educational level. These education group differences have, however, decreased over time in relative terms, but not in absolute terms. Further, there were considerable between-hospitals differences in treatment rates for patients with milder deficits, associated with hospital’s overall stroke thrombolysis rates. Moreover, larger non-university hospitals displayed treatment rate differences between educational groups that were not attributable to patient characteristics. Among thrombolysis-treated women and men, that was independent in ADL before their stroke and survived the first year post-stroke, women experienced higher probability to be dependent in ADL at both 3 and 12 months post-stroke, compared to men. This difference remained significant despite comprehensive adjustments for individual characteristics, symptom severity, and acute effects from stroke thrombolysis. This thesis displays that clinicians face barriers and facilitators at several levels, suggesting implementation interventions could be targeted towards both the individual-, the social interactions and context-, and also the organisation and available resources level. Assurance of clinicians’ individual competence, peer support, and clinical leadership seem to be important areas to intervene. Stroke thrombolysis rates have expanded over time, and an increase in stroke thrombolysis delivery to patients with mild stroke symptoms has contributed to this increase. However, it seems considerable differences between hospitals inhibit equity of care delivery. Further, socioeconomically disadvantaged groups receive less often stroke thrombolysis. Type of hospital seems to play a role, yet the reasons for this difference are not fully understood. This thesis also display that stroke thrombolysis-treated women that survive 1 year after stroke, appears to face higher risk for dependency in ADL, compared to men. / <p>Incorrect ISBN in print version 978-91-760-711-1. Correct ISBN should be 978-91-7601-711-1.</p>